ovarian cancer

ANZGOG contributes to global GCIG Code of Conduct on diversity in gynaecological cancer clinical trials

ANZGOG contributes to global GCIG Code of Conduct on diversity in gynaecological cancer clinical trials ANZGOG has contributed to a new international publication in the International Journal of Gynecological Cancer introducing the GCIG Code of Conduct [...]

ANZGOG contributes to global GCIG Code of Conduct on diversity in gynaecological cancer clinical trials2026-07-08T11:15:06+10:00

More than half of women diagnosed will die — the ovarian cancer reality Australia can’t ignore

More than half of women diagnosed will die — the ovarian cancer reality Australia can’t ignore Ovarian cancer remains the most lethal cancer affecting women, yet it continues to receive a fraction of the attention and investment [...]

More than half of women diagnosed will die — the ovarian cancer reality Australia can’t ignore2026-02-09T14:38:35+11:00

ANZGOG’s ‘On the Down Low’ recognised at the Australian Podcast Awards

ANZGOG's new podcast 'On the Down Low' won 'Best New Podcast' at the Australian Podcast Awards, which celebrate the nation’s best audio talent and creativity. The podcast features raw and inspiring stories from women with ovarian [...]

ANZGOG’s ‘On the Down Low’ recognised at the Australian Podcast Awards2023-10-18T12:02:20+11:00

Mother and daughter educating the doctors of tomorrow about gynaecological cancer

Jenny and her daughter Kathryn are both advocates for ANZGOG’s Survivors Teaching Students (STS) program in QLD, Australia and New Zealand respectively. “One of the first things I wanted to do when diagnosed was [...]

Mother and daughter educating the doctors of tomorrow about gynaecological cancer2023-10-18T12:03:47+11:00

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00
Go to Top